Tumor News and Research

RSS

New method may pave way to effective, targeted cancer treatments

Researchers from the University of Minnesota, Mayo Clinic, and University of Toronto have successfully shown that a new method for targeting mutated cells could create a major breakthrough in a personalized medicine approach to treat cancer.

16 Oct 2013

microRNAs may serve as therapeutic targets and predictors of metastasis

A class of molecules called microRNAs may offer cancer patients two ways to combat their disease.

15 Oct 2013

immatics biotechnologies closes €34 million Series D financing round

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, today announced that it has closed a €34 million Series D financing round.

15 Oct 2013

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Crown Bioscience, Inc., a leading global drug discovery and development service company, today announces that it has entered into a collaboration with Xstrahl Ltd, a leading designer and manufacturer of X-Ray solutions for radiation biology research.

From Xstrahl 15 Oct 2013

Barcelona to host European Drosophila Research Conference

From 16 to 19 October, more than 700 international scientists will attend the European Drosophila Research Conference, the most important European conference focused on basic and biomedical research that uses the fly fruit, Drosophila melanogaster, as a model system.

15 Oct 2013

Results announced for Phase II PRECEDENT trial of vintafolide for treatment of platinum-resistant ovarian cancer

Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology.

15 Oct 2013

NICE issues second draft guidance on PIXUVRI for treatment of aggressive B-cell NHL

Cell Therapeutics, Inc. today announced that the National Institute for Health and Care Excellence, a non-departmental public body of the Department of Health in the United Kingdom, issued second draft guidance on PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

15 Oct 2013

Cdk5 protein may play crucial role in deadly form of thyroid cancer

A specific protein once thought to exist only in the brain may play a crucial role in a deadly form of thyroid cancer, as well as other cancers, and provide a fresh target for researchers seeking ways to stop its progression, UT Southwestern Medical Center researchers report today in Cancer Cell.

15 Oct 2013

Study provides novel link between cellular aging and diffuse large B-cell lymphoma

Scientists at the University of Massachusetts Medical School have shown that diffuse large B-cell lymphoma (DLBCL) may be susceptible to treatment by re-activating the normal aging program in tumor cells so they can no longer divide.

15 Oct 2013

Bladder involvement can lead to prostate cancer misdiagnosis

Men with lesions in the neck, trigone, or posterior wall of the bladder should be tested for basal prostate cancer as well as bladder cancer to ensure that they are not misdiagnosed, say researchers.

14 Oct 2013

Football-shaped artificial particles teach immune cells to recognize, destroy cancer cells

Researchers at Johns Hopkins have succeeded in making flattened, football-shaped artificial particles that impersonate immune cells. These football-shaped particles seem to be better than the typical basketball-shaped particles at teaching immune cells to recognize and destroy cancer cells in mice.

14 Oct 2013

Resveratrol can make tumor cells more susceptible to radiation treatment

A recent study by a University of Missouri researcher shows that resveratrol, a compound found in grape skins and red wine, can make certain tumor cells more susceptible to radiation treatment. This research, which studied melanoma cells, follows a previous MU study that found similar results in the treatment of prostate cancer.

12 Oct 2013

Research findings may lead to new ways to combat cancer

The way cells divide to form new cells - to support growth, to repair damaged tissues, or simply to maintain our healthy adult functioning - is controlled in previously unsuspected ways UC San Francisco researchers have discovered.

12 Oct 2013

Novartis Inks Agreement For Immunogen's "TAP" ADC Technology

...

11 Oct 2013

Novartis Inks Agreement For Immunogen's "TAP" ADC Technology

...

11 Oct 2013

High voltage, short pulsed electric fields destroy cells in skin tissue, lead to scarless tissue regeneration

High voltage, short pulsed electric fields, used for disinfection and solid tumor destruction, selectively damage cell membranes, while preserving overall tissue structure, a phenomenon that may be a key factor in scarless tissue regeneration.

11 Oct 2013

ImmunoGen signs new license agreement with Novartis

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, today announced that Novartis has licensed the exclusive right to use the Company's ADC technology to develop anticancer therapeutics to an undisclosed target.

11 Oct 2013

New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

Cancer immunotherapy can successfully use the body's own immune system to kill tumor cells. But some current approaches to stimulate an antitumor immune response are short-lived, with limited clinical effectiveness. A new gene transfer strategy that introduces modified, immune-stimulating human stem cells is both feasible and effective for achieving persistent immunotherapy to treat leukemias and lymophomas, according to a study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

11 Oct 2013

Scientists to combine NK cell therapy with immunocytokine to target childhood cancer

Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies. Now for the first time, scientists will combine NK cell therapy with an immunocytokine to target children with relapsed/refractory disease including those with bulky tumors.

11 Oct 2013

Researchers find ways to identify, isolate HCC progenitor cells before tumors become evident

For the first time, researchers at the University of California, San Diego School of Medicine have isolated and characterized the progenitor cells that eventually give rise to malignant hepatocellular carcinoma tumors - the most common form of liver cancer. The researchers found ways to identify and isolate the HCC progenitor cells long before actual tumors were apparent.

11 Oct 2013

Tumor News and Research

New method may pave way to effective, targeted cancer treatments

microRNAs may serve as therapeutic targets and predictors of metastasis

immatics biotechnologies closes €34 million Series D financing round

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Barcelona to host European Drosophila Research Conference

Results announced for Phase II PRECEDENT trial of vintafolide for treatment of platinum-resistant ovarian cancer

NICE issues second draft guidance on PIXUVRI for treatment of aggressive B-cell NHL

Cdk5 protein may play crucial role in deadly form of thyroid cancer

Study provides novel link between cellular aging and diffuse large B-cell lymphoma

Bladder involvement can lead to prostate cancer misdiagnosis

Football-shaped artificial particles teach immune cells to recognize, destroy cancer cells

Resveratrol can make tumor cells more susceptible to radiation treatment

Research findings may lead to new ways to combat cancer

Novartis Inks Agreement For Immunogen's "TAP" ADC Technology

Novartis Inks Agreement For Immunogen's "TAP" ADC Technology

High voltage, short pulsed electric fields destroy cells in skin tissue, lead to scarless tissue regeneration

ImmunoGen signs new license agreement with Novartis

New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

Scientists to combine NK cell therapy with immunocytokine to target childhood cancer

Researchers find ways to identify, isolate HCC progenitor cells before tumors become evident

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News